Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRent ExpenseShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Alterity Therapeutics (ATHE) EBIAT (2016 - 2024)

Alterity Therapeutics has reported EBIAT over the past 4 years, most recently at -$8.8 million for Q2 2019.

  • For Q2 2019, EBIAT fell 13995.44% year-over-year to -$8.8 million; the TTM value through Jun 2019 reached -$9.9 million, down 4701.53%, while the annual FY2025 figure was -$7.9 million, 37.22% up from the prior year.
  • EBIAT for Q2 2019 was -$8.8 million at Alterity Therapeutics, down from -$3.8 million in the prior quarter.
  • Over five years, EBIAT peaked at $2.8 million in Q4 2017 and troughed at -$8.8 million in Q2 2019.
  • A 4-year average of -$2.7 million and a median of -$3.8 million in 2018 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: surged 98.9% in 2018 and later crashed 13995.44% in 2019.
  • Year by year, EBIAT stood at $2.7 million in 2016, then increased by 1.55% to $2.8 million in 2017, then plummeted by 237.71% to -$3.8 million in 2018, then crashed by 130.23% to -$8.8 million in 2019.
  • Business Quant data shows EBIAT for ATHE at -$8.8 million in Q2 2019, -$3.8 million in Q4 2018, and -$62574.7 in Q2 2018.